secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apollo Endosurgery, Inc. (—)
CIK:        0001251769
Form:       8-K
Filed at:   2023-04-04T23:59:59+00:00
Accession:  0001193125-23-090389
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 2.04, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apollo Endosurgery completes Boston Scientific acquisition for $10 per share cash
--------------------------------------------------------------------------------

- Merger closed April 4, 2023; shareholders received $10.00 per share in cash.
- Shares suspended from Nasdaq; Company to file Form 15 to suspend SEC reporting.
- Entire board of directors and all executive officers resigned; replaced by Boston Scientific designees.
- Loan and Security Agreement with Innovatus Life Sciences terminated and paid in full.
- All outstanding stock options and RSUs cashed out; PSUs vested at target at merger close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1251769/000119312523090389/0001193125-23-090389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1251769/000119312523090389/d464566d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-090389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer